Research
Hormonal
Patients receiving semaglutide within 10 days of surgery have a significantly increased risk of residual gastric content compared to a control sample (40% vs. 3%).
Clinicians should be cautious when managing patients on semaglutide in the peri-operative setting due to increased aspiration risk.
StrongSupportsmedium confidence
Out of 220 patients, they observed a significantly increased risk of residual gastric content in patients receiving semaglutide within 10 days of surgery compared with a convenience control sample (40% vs. 3%).
Why this rating
The study is based on an observational cohort design with a significant sample size.
Source
Gastric point‐of‐care ultrasound in the GLP‐1 receptor agonist era: clinical impact and competency
Dáire N. Kelly et al. · Anaesthesia · 2025
DOI 10.1111/anae.16548
cohort · n=220Cited 3×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →